S-1: Nexalin Technology Seeks Up to $7 Million in Common Stock Offering

Nexalin Technology is offering up to $7 million of its common stock in a best effort offering to fund general corporate purposes.

Summary

• Nexalin Technology, Inc. has filed a registration statement for a proposed offering of up to $7,000,000 of its common stock.
• The offering will be conducted on a reasonable best effort basis through Maxim Group LLC, acting as the exclusive placement agent.
• The assumed public offering price is not yet determined and will be fixed.
• The offering is expected to close within two business days following the commencement of sales.
• The company intends to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures.
• Nexalin Technology is an emerging growth company and a smaller reporting company, which allows it to comply with reduced public company reporting requirements.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol NXL.
• The last reported sale price of the common stock on May 22, 2024, was $1.14 per share.

Sentiment

Score: 5

Explanation: The document presents a neutral outlook. While it highlights the company's plans for growth and development, it also acknowledges the significant risks and challenges associated with its business.

Positives

• The company's Gen-2 device was approved in China by the NMPA for the treatment of insomnia and depression.
• The company is developing a new virtual clinic that will allow physicians to diagnose and treat mental health issues remotely.
• The company plans to conduct decentralized clinical trials for the Gen-3 device in the U.S.

Negatives

• The company has incurred significant losses since its inception and expects to incur losses over the next several years.
• The company may not be able to continue as a going concern if it does not execute its business plan or obtain additional financing.
• The company is dependent on the success of its future products, some of which are in clinical development but have not completed advanced clinical trials.
• The company relies on third parties to conduct the clinical trials for its products, and those third parties may not perform satisfactorily.
• The company may eventually compete for product sales with other companies, many of which will have greater resources or capabilities than it has.
• The company may be subject to PRC laws relating to, among others, data security and restrictions over foreign investments.

Risks

• The company has incurred significant losses since its inception and may never achieve or maintain profitability.
• The company's independent accountants audit report included in the 2023 Form 10-K states that there is substantial doubt about the company's ability to continue as a going concern.
• The company may require additional funding to meet its financial needs and to pursue its business objectives.
• The company depends on the success of its future products, some of which are in clinical development but have not completed advanced clinical trials.
• The company relies on third parties to conduct the clinical trials for its products, and those third parties may not perform satisfactorily.
• The company may eventually compete for product sales with other companies, many of which will have greater resources or capabilities than it has.
• The company may be subject to PRC laws relating to, among others, data security and restrictions over foreign investments.
• If you purchase shares in this offering, you will suffer immediate and substantial dilution of your investment.
• The trading price of the company's common stock may be volatile, and you could lose all or part of your investment.
• If the company is not able to comply with the applicable continued listing requirements or standards of The Nasdaq Stock Market, Nasdaq could delist the company's common stock.

Future Outlook

The company intends to use the net proceeds of this offering for general corporate purposes, including working capital, operating expenses, and capital expenditures.

Industry Context

The company operates in the neurostimulation market, which is competitive and rapidly evolving. The company competes with traditional pharmaceutical therapies, other neurostimulators, and implanted devices.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the document mentions that the company competes with traditional pharmaceutical therapies, other neurostimulators, and implanted devices.
• These are all common treatment options for mental health disorders, so the company's products will need to be competitive in terms of efficacy, safety, and cost to gain market share.

Related Party Transactions

• Wider Come Limited (Wider), a related party, is obligated to fund all operations for the initial 12-month period of the Joint Venture, after which Nexalin and Wider plan to jointly fund the Joint Ventures operating expenses in accordance with their pro rata ownership.
• Under the preceding terms of the collaborative arrangement between the Company and Wider, Wider served as an authorized distributor of the Companys Gen-2 devices in Asia.
• As part of the consideration for Widers performance of its obligations to the Company prior to the formalization of the Joint Venture, the Company and certain designated Wider shareholders entered into stock issuance agreements for the issuance of 450,000 shares of the Companys common stock, and simultaneously with the execution of this service agreement, Wider invested $200,000 to the Company.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The company's ability to develop and commercialize its products will impact its employees, customers, and suppliers.
• The company's financial performance will impact its creditors.

Next Steps

• The company will continue its ongoing and planned preclinical and clinical development of its existing and next Generation devices.
• The company will initiate preclinical studies and clinical trials for any additional products that it may pursue in the future.
• The company will seek to discover and develop additional treatment indications.
• The company will seek regulatory approvals for any products that successfully complete clinical trials.
• The company will ultimately establish sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any product for which it may obtain regulatory approval and intend to commercialize on its own.

Key Dates

Keywords

common stock, offering, Nexalin Technology, Maxim Group LLC, neurostimulation, mental health, clinical trials, FDA, China, Gen-2, Gen-3